{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:30:28Z","timestamp":1790566228193,"version":"4.1.0"},"reference-count":21,"publisher":"Georg Thieme Verlag KG","issue":"03","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>This retrospective study, utilizing U.S. electronic health record (EHR) data from January 2013 to December 2020, sought to assess whether rivaroxaban and apixaban had similar effectiveness and safety in the treatment of cancer-associated venous thromboembolism (VTE) in patients with a cancer type not associated with a high risk of bleeding. We included adults diagnosed with active cancer, excluding esophageal, gastric, unresected colorectal, bladder, noncerebral central nervous system cancers and leukemia, who experienced VTE and received a therapeutic VTE dose of rivaroxaban or apixaban on day 7 post-VTE, and were active in the EHR \u226512 months prior to the VTE. Primary outcome was the composite of recurrent VTE or any bleed resulting in hospitalization at 3 months. Secondary outcomes included recurrent VTE, any bleed resulting in hospitalization, any critical organ bleed, and composites of these outcomes at 3 and 6 months. Inverse probability of treatment-weighted Cox regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs). We included 1,344 apixaban and 1,093 rivaroxaban patients. At 3 months, rivaroxaban was found to have similar hazard to apixaban for developing recurrent VTE or any bleed resulting in hospitalization (HR: 0.87; 95% CI: 0.60\u20131.27). No differences were observed between cohorts for this outcome at 6 months (HR: 1.00; 95% CI: 0.71\u20131.40) or for any other outcome at 3 or 6 months. In conclusion, patients receiving rivaroxaban or apixaban showed similar risks of the composite of recurrent VTE or any bleed resulting in hospitalization in patients with cancer-associated VTE. This study was registered at www.clinicaltrials.gov as #NCT05461807.<\/jats:p><jats:p>\n            Key Points\n          <\/jats:p>","DOI":"10.1055\/s-0043-1770783","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T23:36:56Z","timestamp":1689032216000},"page":"e206-e216","source":"Crossref","is-referenced-by-count":10,"title":["Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding"],"prefix":"10.1055","volume":"07","author":[{"given":"Kimberly Snow","family":"Caroti","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, School of Pharmacy, University of Connecticut, Storrs, Connecticut, United States"},{"name":"Evidence-Based Practice Center, Hartford Hospital, Hartford, Connecticut, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Becattini","sequence":"additional","affiliation":[{"name":"Department of Internal and Emergency Medicine \u2013 Stroke Unit, University of Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Haematological Medicine, Guy's and St Thomas' NHS Foundation Trust, King's College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Ekbom","sequence":"additional","affiliation":[{"name":"Unit of Clinical Epidemiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok A.","family":"Khorana","sequence":"additional","affiliation":[{"name":"Cleveland Clinic and Case Comprehensive Cancer Center, Cleveland, Ohio, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes Y.Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia and BC Cancer, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Brescia","sequence":"additional","affiliation":[{"name":"Freshtech IT, LLC, East Hartford, Connecticut, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Abdelgawwad","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology Group, Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Psaroudakis","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology Group, Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Rivera","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology Group, Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Schaefer","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology Group, Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Brobert","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology Group, Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4868-7158","authenticated-orcid":false,"given":"Craig I.","family":"Coleman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, School of Pharmacy, University of Connecticut, Storrs, Connecticut, United States"},{"name":"Evidence-Based Practice Center, Hartford Hospital, Hartford, Connecticut, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"issue":"08","key":"ref1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"J A Heit","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"17","key":"ref2","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","article-title":"Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis","volume":"18","author":"B A Hutten","year":"2000","journal-title":"J Clin Oncol"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"P Prandoni","year":"2002","journal-title":"Blood"},{"issue":"09","key":"ref4","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"A A Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"N S Key","year":"2020","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"S V Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"G H Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"07","key":"ref8","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"D Farge","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"ref9","first-page":"1181","article-title":"Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"M B Streiff","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"03","key":"ref10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jaccao.2020.06.001","article-title":"Direct oral anticoagulants in patients with active cancer: a systematic review and meta-analysis","volume":"2","author":"J Sabatino","year":"2020","journal-title":"JACC Cardiooncol"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.thromres.2010.03.009","article-title":"Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States","volume":"126","author":"R H White","year":"2010","journal-title":"Thromb Res"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use","volume":"20","author":"A Cunningham","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/jama.2012.96867","article-title":"Prespecified falsification end points: can they validate true observational associations?","volume":"309","author":"V Prasad","year":"2013","journal-title":"JAMA"},{"issue":"07","key":"ref15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"G E Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"S 01","key":"ref16","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2021-151566","article-title":"Patient characteristics and temporal changes in anticoagulation treatment patterns in patients diagnosed with cancer-associated thrombosis: an Oscar-US Analysis","volume":"138","author":"C Coleman","year":"2021","journal-title":"Blood"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"P C Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"S M Langan","year":"2018","journal-title":"BMJ"},{"issue":"02","key":"ref19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.mayocp.2020.10.041","article-title":"Direct oral anticoagulants compared with dalteparin for treatment of cancer-associated thrombosis: a living, interactive systematic review and network meta-analysis","volume":"97","author":"I B Riaz","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"675969","DOI":"10.3389\/fcvm.2021.675969","article-title":"Patient characteristics and preferences regarding anticoagulant treatment in venous thromboembolic disease","volume":"8","author":"D Lan\u00e9elle","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijcard.2016.03.212","article-title":"Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke","volume":"215","author":"M J Alberts","year":"2016","journal-title":"Int J Cardiol"},{"key":"ref22","first-page":"215","article-title":"Administrative databases and outcomes assessment: an overview of issues and potential utility","volume":"5","author":"S K Gandhi","year":"1999","journal-title":"J Manag Care Pharm"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1770783.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T17:55:16Z","timestamp":1690394116000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1770783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":21,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2023,7,5]]},"published-print":{"date-parts":[[2023,7]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1770783","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"value":"2512-9465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}